Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Amycretin, an oral weight loss pill developed by the makers of Wegovy, led to a 13.1% weight loss over three months in early ...

Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued ...

A daily diet pill has shown promising results in early trials, with participants losing an average of 13% of their body ...

Amycretin mimics the actions of glucagon-like peptide-1 (GLP-1) and amylin, hormones that play a role in reducing blood sugar ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms ...

This news of Ozempic price cuts comes on the heels, or tablet, of Novo Nordisk developing a weight loss pill that mirrors the ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

Terns Pharmaceuticals (NASDAQ: TERN) is one of them. The fledgling clinical-stage drugmaker recently reported positive ...